Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Endocyte

Drug Profile

Research programme: cancer therapeutics - Endocyte

Alternative Names: CB-3717; EC 0531; EC 0651; EC 1812; EC 1868; EC 1977; EC 2629; EC-1744; EC1788; GARFTase inhibitors - Endocyte; PNU-159682

Latest Information Update: 31 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endocyte
  • Class Depsipeptides; Doxorubicins; Drug conjugates; Folic acids; Oligopeptides; Small molecules; Taxanes
  • Mechanism of Action Folate receptor 1 antagonists; Phosphoribosylglycinamide formyltransferase inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 21 Dec 2018 Endocyte has been acquired by Novartis
  • 09 Feb 2018 EC 2629 is still in non-clinical development for Solid tumours in USA (Endocyte website, Feb 2018)
  • 09 Feb 2018 EC 2629 is available for licensing as of 09 Feb 2017. http://endocyte.com/technology/partnering/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top